REGENXBIO Inc. (RGNX): Price and Financial Metrics

REGENXBIO Inc. (RGNX): $21.07

1.11 (-5.00%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add RGNX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#182 of 365

in industry

RGNX Price/Volume Stats

Current price $21.07 52-week high $28.80
Prev. close $22.18 52-week low $11.83
Day low $20.94 Volume 487,000
Day high $22.42 Avg. volume 799,005
50-day MA $18.26 Dividend yield N/A
200-day MA $17.96 Market Cap 936.10M

RGNX Stock Price Chart Interactive Chart >

RGNX POWR Grades

  • Value is the dimension where RGNX ranks best; there it ranks ahead of 68.25% of US stocks.
  • The strongest trend for RGNX is in Value, which has been heading down over the past 26 weeks.
  • RGNX's current lowest rank is in the Sentiment metric (where it is better than 5.57% of US stocks).

RGNX Stock Summary

  • RGNX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.9 -- higher than only 11.69% of US-listed equities with positive expected earnings growth.
  • In terms of twelve month growth in earnings before interest and taxes, REGENXBIO INC is reporting a growth rate of -323.02%; that's higher than merely 4.02% of US stocks.
  • As for revenue growth, note that RGNX's revenue has grown -79.3% over the past 12 months; that beats the revenue growth of merely 2.23% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to REGENXBIO INC, a group of peers worth examining would be BOLT, CUE, AEVA, ENTA, and STRO.
  • RGNX's SEC filings can be seen here. And to visit REGENXBIO INC's official web site, go to www.regenxbio.com.

RGNX Valuation Summary

  • RGNX's EV/EBIT ratio is -3.3; this is 122.6% lower than that of the median Healthcare stock.
  • RGNX's price/sales ratio has moved down 197.9 over the prior 101 months.

Below are key valuation metrics over time for RGNX.

Stock Date P/S P/B P/E EV/EBIT
RGNX 2023-12-29 7.9 2.2 -3.0 -3.3
RGNX 2023-12-28 8.2 2.2 -3.1 -3.4
RGNX 2023-12-27 8.4 2.3 -3.2 -3.5
RGNX 2023-12-26 8.3 2.3 -3.2 -3.4
RGNX 2023-12-22 8.2 2.3 -3.1 -3.4
RGNX 2023-12-21 8.2 2.2 -3.1 -3.4

RGNX Growth Metrics

    The year over year net cashflow from operations growth rate now stands at 442.33%.
  • Its year over year revenue growth rate is now at 204.02%.
  • The 5 year revenue growth rate now stands at 1017.89%.
RGNX's revenue has moved up $444,801,000 over the prior 33 months.

The table below shows RGNX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 480.034 158.121 73.637
2022-06-30 484.295 172.218 90.716
2022-03-31 473.681 204.095 101.256
2021-12-31 470.347 218.875 127.84
2021-09-30 93.137 -67.894 -212.424
2021-06-30 161.276 -67.995 -145.228

RGNX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RGNX has a Quality Grade of D, ranking ahead of 18.52% of graded US stocks.
  • RGNX's asset turnover comes in at 0.116 -- ranking 250th of 682 Pharmaceutical Products stocks.
  • PTGX, ARDX, and CBAY are the stocks whose asset turnover ratios are most correlated with RGNX.

The table below shows RGNX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.116 0.581 -0.362
2021-06-30 0.218 0.738 -0.257
2021-03-31 0.242 0.762 -0.255
2020-12-31 0.286 0.769 -0.281
2020-09-30 0.297 0.798 -0.244
2020-06-30 0.126 0.763 -0.367

RGNX Price Target

For more insight on analysts targets of RGNX, see our RGNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $64.00 Average Broker Recommendation 1.5 (Moderate Buy)

REGENXBIO Inc. (RGNX) Company Bio


REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company was founded in 2009 and is based in Rockville, Maryland.


RGNX Latest News Stream


Event/Time News Detail
Loading, please wait...

RGNX Latest Social Stream


Loading social stream, please wait...

View Full RGNX Social Stream

Latest RGNX News From Around the Web

Below are the latest news stories about REGENXBIO INC that investors may wish to consider to help them evaluate RGNX as an investment opportunity.

Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares

Kenneth Mills, President and CEO of Regenxbio Inc (NASDAQ:RGNX), executed a sale of 45,000 shares in the company on December 19, 2023, according to a recent SEC Filing.

Yahoo | December 22, 2023

REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial

REGENXBIO Inc. (Nasdaq: RGNX) today announced that the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE® trial. RGX-202 is an investigational one-time AAV Therapeutic for Duchenne muscular dystrophy (Duchenne), using the NAV® AAV8 vector to deliver a transgene for a novel microdystrophin that includes the functional elements of the C-Terminal (CT) domain as well as a muscle-specific promoter to support a targeted therapy for improved resistance to muscle damage

Yahoo | November 29, 2023

Wall Street Analysts Believe Regenxbio (RGNX) Could Rally 95.61%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 95.6% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 16, 2023

REGENXBIO (NASDAQ:RGNX) adds US$111m to market cap in the past 7 days, though investors from five years ago are still down 72%

REGENXBIO Inc. ( NASDAQ:RGNX ) shareholders should be happy to see the share price up 16% in the last week. But will...

Yahoo | November 12, 2023

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript November 8, 2023 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.41, expectations were $-1.44. Operator: Good day, and thank you for standing by. Welcome to REGENXBIO’s Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, […]

Yahoo | November 9, 2023

Read More 'RGNX' Stories Here

RGNX Price Returns

1-mo 5.88%
3-mo 17.38%
6-mo 28.01%
1-year 16.54%
3-year -37.31%
5-year -63.24%
YTD 17.38%
2023 -20.86%
2022 -30.64%
2021 -27.91%
2020 10.72%
2019 -2.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!